BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Hold” from Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) has received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $59.40.

Several equities analysts recently issued reports on the company. TheStreet cut BioLife Solutions from a “c-” rating to a “d” rating in a research report on Tuesday, April 12th. B. Riley lowered their price objective on BioLife Solutions from $67.00 to $48.00 in a research report on Wednesday, March 2nd. Oppenheimer raised BioLife Solutions from a “market perform” rating to an “outperform” rating in a research report on Monday, April 25th. StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research note on Friday, March 25th. Finally, Zacks Investment Research lowered shares of BioLife Solutions from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 3rd.

In related news, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 2nd. The shares were sold at an average price of $29.88, for a total value of $298,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Rice sold 24,400 shares of the company’s stock in a transaction on Monday, April 18th. The stock was sold at an average price of $17.59, for a total transaction of $429,196.00. Following the completion of the transaction, the chief executive officer now directly owns 360,491 shares of the company’s stock, valued at approximately $6,341,036.69. The disclosure for this sale can be found here. Insiders sold a total of 194,756 shares of company stock valued at $4,180,456 over the last 90 days. 5.90% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in BioLife Solutions by 26.5% in the 4th quarter. Russell Investments Group Ltd. now owns 512,871 shares of the medical equipment provider’s stock worth $19,113,000 after buying an additional 107,584 shares during the period. Public Sector Pension Investment Board bought a new position in BioLife Solutions in the 3rd quarter worth $2,487,000. BlackRock Inc. boosted its holdings in BioLife Solutions by 122.9% in the 3rd quarter. BlackRock Inc. now owns 4,228,452 shares of the medical equipment provider’s stock worth $178,947,000 after buying an additional 2,331,680 shares during the period. SG Americas Securities LLC bought a new position in BioLife Solutions in the 3rd quarter worth $1,282,000. Finally, Horan Capital Advisors LLC. bought a new position in BioLife Solutions in the 3rd quarter worth $297,000. 79.62% of the stock is owned by institutional investors.

Shares of BLFS opened at $12.67 on Friday. The company has a quick ratio of 2.41, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $20.63 and its 200-day moving average price is $31.42. BioLife Solutions has a 52 week low of $12.13 and a 52 week high of $60.67. The stock has a market cap of $533.34 million, a P/E ratio of -60.33 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS – Get Rating) last released its quarterly earnings data on Monday, February 28th. The medical equipment provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.25). The business had revenue of $37.30 million during the quarter, compared to the consensus estimate of $37.28 million. BioLife Solutions had a negative net margin of 7.04% and a negative return on equity of 5.19%. During the same period last year, the company posted ($0.01) earnings per share. On average, equities analysts anticipate that BioLife Solutions will post -0.13 EPS for the current year.

About BioLife Solutions (Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also